Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 15, 2026
TickeronGET DAILY SIGNALS
Alnylam Pharmaceuticals (ALNY) Drops -28.8% Over 30 Days After Q3 Results and Guidance Update

Alnylam Pharmaceuticals (ALNY) Drops -28.8% Over 30 Days After Q3 Results and Guidance Update

Key Takeaways

  • Alnylam Pharmaceuticals (ALNY) fell roughly 28.8% over the trailing 30 days, from a close near $231.83 to about $165.04.
  • The decline was concentrated in a 25.1% single-day drop on October 29, 2026, following third-quarter results and cautious full-year guidance.
  • Third-quarter revenue of $1.46 billion rose 17% year over year and beat estimates, but management said TTR product sales would likely land at the low end of its $4.2 billion–$4.5 billion range.
  • U.S. total transthyretin (TTR) demand growth slowed to $81 million from $129 million in the prior quarter, and management said it was "not yet satisfied" with underlying demand growth.
  • Several analysts downgraded the stock or trimmed price targets, citing slower AMVUTTRA growth, payer restrictions, and proposed 340B reimbursement changes.
  • Over the trailing quarter, shares have declined about 28%, extending a broader multi-month downtrend.

Alnylam Pharmaceuticals (ALNY) Company Overview and Market Position

Alnylam Pharmaceuticals is a Cambridge, Massachusetts-based biotechnology company and a pioneer in RNA interference (RNAi) therapeutics, a platform that silences disease-causing genes by targeting messenger RNA. Its commercial portfolio includes AMVUTTRA (vutrisiran) and ONPATTRO (patisiran) for transthyretin-mediated (ATTR) amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1. AMVUTTRA is the company's flagship product and accounts for the large majority of product sales, driven by its approval in ATTR amyloidosis with cardiomyopathy (ATTR-CM). Alnylam also generates revenue through collaborations with partners including Novartis, Sanofi, and Regeneron. Investors follow the stock closely because of the sizable ATTR-CM market opportunity and a pipeline spanning Huntington's disease and Alzheimer's disease. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Alnylam (ALNY) Stock Price Performance: Last 30 Days vs. Quarter

Over the trailing 30 days, ALNY shares declined from a closing price of $231.83 on October 16 to $165.04 on November 13, a drop of approximately 28.8%. Nearly all of that decline occurred in a single session, when the stock fell 25.1% on October 29 after the company reported third-quarter results.

The quarterly trend tells a similar story. From a close of $228.65 in mid-August, shares are down roughly 28%, after reaching an intra-quarter high near $267 in early September before reversing. The move extends a longer slide: by late October, the stock had lost about 44% over the prior six months and nearly 64% over the prior twelve months.

What Drove ALNY Stock Price in the Last 30 Days

The primary catalyst was Alnylam's third-quarter report on October 29. Although total revenue of $1.46 billion beat consensus estimates and product revenue grew 52% year over year, management signaled that full-year TTR product sales would likely come in at the low end of guidance. U.S. TTR demand growth decelerated to $81 million from $129 million in the prior quarter, and executives acknowledged that converting new physician engagement into patient starts was taking longer than expected.

The report triggered a wave of analyst actions. Stifel downgraded the stock to Hold from Buy and cut its price target to $225 from $318, while AstraZeneca-linked trial-design concerns prompted Bernstein to move to Market Perform from Outperform with a $199 target, down from $376. Morgan Stanley lowered its target to $240 from $300. H.C. Wainwright, by contrast, reiterated a Buy rating and $455 target, describing the selloff as an overreaction. Investor concerns centered on Medicare Advantage step-therapy restrictions, proposed 340B reimbursement changes, and slower first-line AMVUTTRA adoption.

Positive pipeline news, including encouraging Phase 1 data for the Huntington's disease candidate brezosiran announced on October 23, was not enough to offset the commercial and reimbursement worries that drove the decline. From what I see, this highlights how quickly sentiment can shift even when revenue beats occur.

What Drove ALNY Stock Performance Over the Last Quarter

The quarter's weakness reflects a larger re-rating of the company's growth trajectory. Shares had already suffered a sharp one-day decline of 28.3% on July 30, reflecting competitive and pipeline uncertainty in the ATTR-CM space. Since then, concerns about decelerating AMVUTTRA demand, payer access restrictions, and the proposed 340B reimbursement rule have compounded. The company's decision to expand enrollment in the TRITON-CM Phase 3 trial of nucresiran, and to delay its 2027 revenue guidance to mid-February, added to investor caution about near-term visibility. Together, these factors kept sentiment subdued even as Alnylam continued to report revenue growth and advance its broader pipeline.

ALNY Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors are likely to monitor several factors. Alnylam's fourth-quarter and full-year 2026 results, expected in mid-February 2027, will include the company's 2027 product revenue guidance and will be a key test of the demand-growth narrative. Updates on the TRITON-CM Phase 3 trial of nucresiran and the planned 2027 pivotal study for brezosiran in Huntington's disease will shape views on the pipeline. The final outcome of the proposed 340B reimbursement rule and the pace of Medicare Advantage access changes could affect AMVUTTRA's commercial trajectory. Competitive dynamics in ATTR-CM and broader biotech sentiment also remain important variables for the stock's direction. I’m watching this closely as these elements unfold.

Using Tickeron’s Trending AI Robots for Market Context

In my analysis of names like ALNY, I often turn to Tickeron’s Trending AI Robots to see how automated systems are interpreting current momentum. The page curates top-performing bots across strategies and timeframes, helping me compare quantitative approaches without having to build everything from scratch. It gives a useful additional lens on how algorithmic models are positioning around the equities I track, especially during periods of volatility like this one.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: ALNY

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for ALNY turns positive, indicating new upward trend

ALNY saw its Momentum Indicator move above the 0 level on November 13, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 81 similar instances where the indicator turned positive. In 61 of the 81 cases, the stock moved higher in the following days. The odds of a move higher are at 75%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALNY's RSI Indicator exited the oversold zone, 16 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 64%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 65 cases where ALNY's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.

Following a +1.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALNY advanced for three days, in 216 of 297 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.

ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for ALNY turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 29 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 63%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.

The Aroon Indicator for ALNY entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 84 (best 1 - 100 worst), indicating slightly worse than average price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.409) is normal, around the industry mean (3.498). P/E Ratio (26.566) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.330) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (6.911) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALNY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was -18%. PEPG experienced the highest price growth at 77%, while ZURA experienced the biggest fall at -70%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -8%. For the same stocks of the Industry, the average monthly volume growth was -15% and the average quarterly volume growth was -38%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 65
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -4 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of therapeutics based on RNA interference

Industry Biotechnology

Industry
Biotechnology
Address
675 West Kendall Street
Phone
+1 617 551-8200
Employees
2500
Web
https://www.alnylam.com
Interact to see
Advertisement
NVIDIA shares declined roughly 26% over the 30 days ending mid-November, falling from a close near $221 to $162.85. The drop left the stock about 30% below its October 6 record intraday high of $243.37 and at a 52-week low.
Micron shares fell -6.28% to $729.40 from Friday's $778.31 close, gapping lower in premarket trading and holding those losses into Monday's regular session. The decline was sector-driven, not company-specific: memory peers SanDisk, SK hynix and Western Digital slid in tandem as last week's Nvidia CEO departure revived doubts over AI data-center spending, financing and memory demand durability.
Dell Technologies (DELL) fell roughly 23.7% over the last 30 days, sliding from a closing price of $451.71 on October 16, 2026, to $344.53 on November 13, 2026. The decline accelerated after the U.S. midterm elections, when investor concerns about potential AI and data-center regulation triggered a sharp sell-off across AI hardware names.
ACHR fell -7.44% in Monday's regular session, sliding from Friday's $4.03 close to $3.73 shortly after 10 a.m. ET — a third consecutive daily decline that pushed shares back toward their November 5 low. No verified news or fundamental catalyst found for today's leg lower; the selling extends the de-rating that followed Q3 results — revenue of just $5.1 million, a net loss widening 111% to $274.6 million, and price-target cuts from Cantor Fitzgerald, Needham and Canaccord.
SKHY fell -6.87% to $122.74 by 10:04 a.m. ET, down $9.05 from Friday's close of $131.79, extending a premarket decline into the regular session. The drop was driven by a sector-wide AI chip selloff ahead of Nvidia's quarterly results on Tuesday, where CEO Jensen Huang's resignation has raised doubts about the durability of data-center spending that underpins high-bandwidth memory demand.